MEDVi, LLC dba MEDVi

Has MEDVi, LLC dba MEDVi received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued MEDVi, LLC dba MEDVi a warning letter naming semaglutide and tirzepatide, dated Feb 20, 2026, with the FDA subject line “False & Misleading Claims/Misbranded (Telehealth).”

FDA records in this index name MEDVi, LLC dba MEDVi on Feb 20, 2026.

Websites the letters name
medvi.io (see how each letter refers to them)
Type named in FDA records
Telehealth
FDA warning letters
1
Drug recall reports
0
Drugs named
Semaglutide, Tirzepatide
Latest record
Feb 20, 2026

FDA warning letters

Later letters FDA listsLetter
Feb 20, 2026False & Misleading Claims/Misbranded (Telehealth)Semaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Websites named in the letters

Each letter below is addressed to the firm FDA names in it, not to a website. The sentence quoted is the letter’s own reference to the site, copied from the letter on fda.gov.

Drug recalls

No openFDA drug recall reports in this index.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.